Related Experiment Video
Updated: Aug 23, 2025

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Glioma cancer stem cells modulating the local tumor immune environment
Imran Khan1, Sadaf Mahfooz1, Busra Karacam1
1Department of Molecular Biology, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Istanbul, Turkey.
Abstract:
Glioma stem cells (GSCs) drive the resistance mechanism in glioma tumors and mediate the suppression of innate and adaptive immune responses. Here we investigate the expression of mesenchymal-epithelial transition factor (c-Met) and Fas receptor in GSCs and their role in potentiating the tumor-mediated immune suppression through modulation of tumor infiltrating lymphocyte (TIL) population. Tumor tissues were collected from 4 patients who underwent surgery for glioblastoma. GSCs were cultured as neurospheres and evaluated for the co-expression of CD133, c-Met and FasL through flow cytometry. TILs were isolated and evaluated for the lymphocyte subset frequencies including CD3 +, CD4 +, CD8 +, regulatory T cells (FOXP3 + CD25) and microglia (CD11b + CD45) using flow cytometry. Our findings revealed that a significant population of GSCs in all four samples expressed c-Met (89-99%) and FasL (73-97%). A significantly low microglia population was found in local immune cells ranging from 3 to 5%. We did not find a statistically significant correlation between expressions of c-Met + GSC and FasL + GSC with local and systemic immune cells. This may be regarded to the small sample size. The percent c-Met + and FasL + GSC population appeared to be related to percent cytotoxic T cells, regulatory T cells and microglia populations in glioblastoma patients. Further investigation is warranted in a larger sample size.
Insights
Glioma stem cells (GSCs) express c-Met and FasL, potentially suppressing immune responses in glioblastoma. While not statistically significant in this small study, GSC expression correlated with immune cell populations, suggesting a role in immune evasion.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Stem Cell Biology
Background:
- Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) resistance and immune suppression.
- The mesenchymal-epithelial transition factor (c-Met) and Fas receptor are implicated in tumor progression and immune evasion.
Purpose of the Study:
- To investigate the expression of c-Met and Fas receptor in GSCs.
- To explore their role in modulating tumor-infiltrating lymphocytes (TILs) and immune suppression in GBM.
Main Methods:
- Glioblastoma tissues from 4 patients were used to culture GSCs.
- Flow cytometry was employed to assess co-expression of CD133, c-Met, and FasL on GSCs.
- TIL subsets, including T cells and microglia, were analyzed for frequencies.
Main Results:
- A high percentage of GSCs expressed c-Met (89-99%) and FasL (73-97%).
- A low population of microglia (3-5%) was observed in local immune cells.
- No statistically significant correlation was found between GSC marker expression and immune cell populations due to small sample size.
Conclusions:
- GSCs highly express c-Met and FasL, suggesting a role in GBM immune suppression.
- Observed correlations between GSC expression and immune cell populations warrant further investigation in larger cohorts.
Related Concept Videos
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor Immunotherapy
The Tumor Microenvironment

